OTCMKTS:MYCOF Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis → [Webinar] A Deep Dive into Options Volatility: Skew & Relative Value (From OIC) (Ad) Free MYCOF Stock Alerts $0.0053 -0.01 (-65.36%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$0.0053▼$0.005350-Day Range$0.00▼$0.0252-Week Range$0.00▼$0.27Volume153 shsAverage Volume20,148 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Mydecine Innovations Group alerts: Email Address Ad Stansberry ResearchDo This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).Find out how you can too in this free video. About Mydecine Innovations Group Stock (OTCMKTS:MYCOF)Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.Read More MYCOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYCOF Stock News HeadlinesMay 4, 2024 | stockhouse.comMydecine Announces Intention to Refile Certain Financial Statements and Applies for Management Cease Trade OrderMay 3, 2024 | finanznachrichten.deMydecine Innovations Group Inc - Mydecine applies for management cease trade orderMay 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).May 3, 2024 | finanznachrichten.deMydecine Innovations Group Inc - Management cease trade orderApril 18, 2024 | finance.yahoo.comMydecine Innovations Group Inc (0NF0.BE)April 17, 2024 | finance.yahoo.comMydecine Innovations Group Inc (0NF0.MU)April 17, 2024 | stockhouse.comMydecine Innovations Group Inc. Announces Closing Of Share For Debt SettlementApril 9, 2024 | uk.finance.yahoo.comMydecine Innovations Group Inc - SHARE FOR DEBT SETTLEMENTMay 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).March 28, 2024 | uk.finance.yahoo.comMydecine Innovations Group Inc - Mydecine Innovations Group Inc. Announces Closing of Share for Debt SettlementMarch 20, 2024 | finance.yahoo.comMydecine Innovations Group Inc. Announces Share for Debt SettlementFebruary 7, 2024 | finance.yahoo.comMydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of CompoundsFebruary 2, 2024 | finance.yahoo.comMydecine Innovations Group Announces Director ResignationDecember 18, 2023 | uk.finance.yahoo.comMydecine Innovations Group Inc - Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 CompoundDecember 18, 2023 | finance.yahoo.comMydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 CompoundNovember 29, 2023 | finanznachrichten.deMydecine Innovations Group Inc.: Mydecine Announces Update Regarding the Special Access ProgramNovember 28, 2023 | finance.yahoo.comMydecine Announces Update Regarding the Special Access ProgramNovember 17, 2023 | finance.yahoo.comCanadian Securities Exchange Reports October 2023 Performance FiguresOctober 31, 2023 | finance.yahoo.comMydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription AgreementsOctober 26, 2023 | finanznachrichten.deMydecine Innovations Group Inc.: Mydecine Provides Q4 2023 Business UpdateOctober 26, 2023 | financialpost.comMydecine Provides Q4 2023 Business UpdateOctober 25, 2023 | lse.co.ukMydecine Innovations Group Inc Share Price (MYIG.PL)October 16, 2023 | proactiveinvestors.comMydecine Innovations Group gearing up for human trials after completing Aquis listingOctober 13, 2023 | finanznachrichten.deMydecine Innovations Group Inc - Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UKOctober 12, 2023 | benzinga.comPsychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth MarketOctober 12, 2023 | finanznachrichten.deMydecine Innovations Group Inc.: Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UKOctober 12, 2023 | finance.yahoo.comMydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UKSee More Headlines Receive MYCOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2021Today5/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MYCOF CUSIPN/A CIKN/A Webwww.mydecine.com Phone(604) 687-2038FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David Joshua Bartch (Age 36)Co-Founder, CEO, President & Chairman of the Board Comp: $322.62kMr. Robert Roscow M.A.Co-Founder, Chief Scientific Officer & DirectorMr. Damon MichaelsCo-Founder & COOMr. John Charles Ross CA (Age 66)CPA, M.B.A., CFO & Corporate Secretary Comp: $6.68kMr. Sanford M. SteinChief Compliance Officer & General CounselDr. Rakesh Jetly FRCPCM.D., Chief Medical OfficerMorgan KervitskyDirector of MarketingMr. Michel RudolphiePresident of the European OperationsMr. William CookInterim CEO & Technical Director of Mindleap Health Inc.More ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors MYCOF Stock Analysis - Frequently Asked Questions How have MYCOF shares performed in 2024? Mydecine Innovations Group's stock was trading at $0.0149 at the start of the year. Since then, MYCOF stock has decreased by 64.4% and is now trading at $0.0053. View the best growth stocks for 2024 here. How were Mydecine Innovations Group's earnings last quarter? Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) issued its quarterly earnings data on Tuesday, November, 16th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.50. When did Mydecine Innovations Group's stock split? Mydecine Innovations Group shares reverse split on the morning of Thursday, April 21st 2022. The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Mydecine Innovations Group? Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MYCOF) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mydecine Innovations Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.